Cinclus Pharma Holding AB (FRA:J8P) Interest Expense: €-0.22 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:J8P Cinclus Pharma Holding AB FRA:J8P
6 GF Score
Price €1.01
! 3 Warning Signs
View Full Analysis

What is Cinclus Pharma Holding AB Interest Expense?

Cinclus Pharma Holding AB FRA:J8P -2.13% 6 Interest Expense is €-0.22 Mil as of Mar. 2026. GuruFocus rates FRA:J8P with a GF Score™ of 6/100. The stock has 3 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Cinclus Pharma Holding AB's interest expense for the three months ended in Mar. 2026 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.22 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Cinclus Pharma Holding AB's Operating Income for the three months ended in Mar. 2026 was € -8.44 Mil. Cinclus Pharma Holding AB's Interest Expense for the three months ended in Mar. 2026 was € 0.00 Mil. GuruFocus does not calculate Cinclus Pharma Holding AB's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cinclus Pharma Holding AB  (FRA:J8P) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cinclus Pharma Holding AB's Interest Expense for the three months ended in Mar. 2026 was €0.00 Mil. Its Operating Income for the three months ended in Mar. 2026 was €-8.44 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was €0.37 Mil.

Cinclus Pharma Holding AB's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

GuruFocus does not calculate Cinclus Pharma Holding AB's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Cinclus Pharma Holding AB Interest Expense Historical Data

* Premium members only.

The historical data trend for Cinclus Pharma Holding AB's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cinclus Pharma Holding AB Interest Expense Chart

Cinclus Pharma Holding AB Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
-0.00 -0.01 -0.67 -0.76 -0.04

Cinclus Pharma Holding AB Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.22 0.00 0.00 0.00
FRA:J8P
6GF Score
Cinclus Pharma Holding AB FRA:J8P
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cinclus Pharma Holding AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-0.22 Mil mean?
Cinclus Pharma Holding AB (FRA:J8P) has a Interest Expense of €-0.22 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Cinclus Pharma Holding AB and its competitors.
Is Cinclus Pharma Holding AB's Interest Expense too high?
Cinclus Pharma Holding AB's current Interest Expense is €-0.22 Mil. Overall, Cinclus Pharma Holding AB has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Cinclus Pharma Holding AB's Interest Expense compare to ZTS and UTHR?
Cinclus Pharma Holding AB's Interest Expense of €-0.22 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Cinclus Pharma Holding AB and its competitors. Cinclus Pharma Holding AB's current Interest Expense is €-0.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cinclus Pharma Holding AB stock overvalued right now?
Cinclus Pharma Holding AB (FRA:J8P) has a current Interest Expense of €-0.22 Mil. The current Interest Expense is €-0.22 Mil. Cinclus Pharma Holding AB's overall GF Score™ is 6/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Cinclus Pharma Holding AB (FRA:J8P), the current Interest Expense is €-0.22 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cinclus Pharma Holding AB Business Description

Other Exchanges CINPHA:Sweden
Address Kungsbron 1, Stockholm, SWE, SE-111 22
Cinclus Pharma Holding AB is a Swedish clinical-stage pharmaceutical company focused on developing small-molecule treatments for gastric acid-related diseases. Its candidate, linaprazan glurate, is being developed for the treatment of severe gastroesophageal reflux disease, including erosive forms. The company is also developing a dual therapy treatment with an antibiotic targeting Helicobacter pylori, a bacterium found in the gastric and duodenal mucosa. Its primary target population consists of patients with severe erosive gastroesophageal reflux disease, where current treatment options are limited. It operates in Switzerland, Sweden, and the Czech Republic, with the majority of revenue from the Czech Republic.
6GF Score

Get the complete analysis for FRA:J8P

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.01
Price